The Federal Circuit won’t block the launch of MSN Pharmaceuticals Inc.'s copy of the lucrative heart-failure drug Entresto while Novartis Pharmaceuticals Corp. appeals its loss in a patent ...

27 May 2025 Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

The District Court for the District of Delaware recently rejected Novartis’s effort to block MSN Pharmaceuticals from launching a generic version ...

The pharmaceutical company posted higher earnings and sales for the second quarter, and said longtime financial chief Harry ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis could soon face generic competition for Entresto after judge's ruling.